medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2012, Number 3

<< Back Next >>

Arch Neurocien 2012; 17 (3)

Clinical correlation in a sample of Mexican patients with Parkinson’s disease

Morales-Briceño H, RodrÍguez-Violante M, Cervantes-Arriaga A

Language: Spanish
References: 20
Page: 152-158
PDF size: 121.05 Kb.


ABSTRACT

Parkinson’s disease (PD) is a neurodegenerative disease. During its progression have some clinical properties as dysphagia, immobility, depression and dementia may alter food intake, contributing to malnutrition. This research aims to determine the prevalence of overweight and obesity in a sample of PD patients treated at the Clinic of abnormal movements in the National Institute of Neurology and Neurosurgery, and comparative analysis. We studied 177 patients with PD who met Brain Bank Queen Square and 177 matched healthy controls. Overweight and obesity are common among Mexican patients with PD, while the low weight is almost negligible.


REFERENCES

  1. Jost WH. Gastrointestinal motility problems in patients with Parkinson’s disease. Drugs Aging 1997;10:249-58.

  2. Nozaki S, Saito T, Matsumura T. Relationship between weight loss and dysphagia in patients with Parkinson’s disease. Rhinsho Shinkeigaku 1999; 39:1010-4.

  3. Jankovic J, McDermott M, Carter J. Variable expression of Parkinson’s disease: a base -line analysis of the DATATOP cohor t. The Parkinson Study Group. Neurology 1990; 40:1529-34.

  4. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000;23:34-44.

  5. Parkinson Study Group. A Randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. Arch Neurol 2005; 62:241-8.

  6. Kim HJ, Oh ES, Lee JH. Relationship between changes of body mass index and cognitive decline in Parkinson’s disease. Arch Gerontol Geriatr 2001; doi: 10.1016/ jarchger.2011.06.022.

  7. Bachmann CG, Zapf A, Brunner E. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesia. Eur J Neurol 2009;16:895-901.

  8. Cecchini M, Sassi F, Lauer JA. Tackling of unhealthy diets, physical inactivity, and obesity: health ef fects and costeffectiveness. Lancet 2010;376:1775-84.

  9. Ayala GX, Elder JP, Campbell NR. Correlates of body mass index and waist-tohip ratio among Mexican women in the United States: Implications for inter vention development. Women Health Issues 2004;14:155-64.

  10. Gutiérrez LM, Llaca MC, Cervantes L. Overweight in elderly Mexican women of a marginal community. J Nutr Health Aging 2001; 5:256-8.

  11. Barichella M, Marczewska A, Vairo A. Is underweight-ness still a major problem in Parkinson´s disease patients? Eur J Clin Nut 2003;57:543-47.

  12. Jaafar AF, Gray WK, Porter B. A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson’s disease. BMC Neurol 2010;10:124.

  13. Barichella M, Villa MC, Massarotto A. Mini Nutritional Assessment in patients with Parkinson’s disease: correlation between worsening of the malnutrition and increasing number of disease-years. Nutr Neurosci 2008;11:128-34.

  14. Beyer PL, Palarino MY, Michalek D. Weight change and body composition in patients with Parkinson’s disease. J Am Diet 1995; 95:979-83.

  15. Sharma JC, Macnamara L, Hasoon M. Cascade of levodopa dose and weightrelated dyskinesia in Parkinson’s disease (LD–WD-PD cascade). Parkinsonism Relat Disord 2006; 12:499-505.

  16. Walker RW, Howells AR, Gray WK. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord 2011;17:27-9.

  17. Block G, Liss C, Reines S. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group.Eur Neurol 1997;37:23-7.

  18. Zappia M, Crescibene L, Arabia G. Body weight influences pharmacokinetics of levodopa in Parkinson’s disease. Clin Neuropharmacol 2002; 25:79-82.

  19. Müller T, Woitalla D, Saft C. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000; 6:171-3.

  20. Kumru H, Santamaría J, Valldeoriola F. Increase in body weight after pramipexole treatment in Parkinson’s disease. Mov Disord 2006; 21:1972-4.




2020     |     www.medigraphic.com